胃癌术后腹腔热灌注联合静脉化疗应用探究.docVIP

胃癌术后腹腔热灌注联合静脉化疗应用探究 　 作者：陈军 吴泰璜 苏妍 宋钊 林黎明 【摘要】目的： 研究 胃癌术后腹腔热灌注化疗联合静脉化疗的 治疗 效果。 方法 ：140例胃癌根治术后患者随机分为腹腔热灌注组（n=72）和静脉化疗组（n=68）。腹腔热灌注组患者在静脉化疗同时 应用 腹腔热灌注化疗，观察两组术后并发症、不良反应、术后生存率及腹腔复发率。结果：两组在术后并发症及不良反应无显著性差异。术后3、5年生存率腹腔热灌注组和静脉化疗组分别为86.1%、60.2%和58.3%、29.4%（P＜0.05）；术后3、5年腹腔复发率分别为5.6%、27.8%和20.6%、53%（P＜0.05）。结论：胃癌术后腹腔热灌注联合静脉化疗可有效控制复发和转移，提高胃癌术后病人的生存率和生存质量。 【关键词】胃肿瘤#12539;腹腔热灌注化疗#12539;静脉化疗 Clinical study of postoperative intraperitoneal hyperthermic perfusion combined with venoclysis for gastric cancer 论文代写 【ABSTRACT】Objective:To study the effect of intraperitoneal hyperthermic perfusion chemotherapy combined with venoclysis on postoperative gastric cancer.Methods:140 postoperative patients with gastric cancer were divided into IPHPC group(n=72) and chemotherapy of venoclysis group(n=68). The intraperitoneal hyperthermic perfusion chemotherapy and chemotherapy of venoclysis were applied for the patients in IPHPC group at one time.Postoperative complications,toxicity,survival rate and peritoneal recurrence rate in two groups were observed.Results:There was no sharp difference in the postoperative complications and toxicity between the two groups.The 3，5 yearsurvival rate were 86.1%,60.2% and 58.3%,29.4% in IPHPC group and CV group.The 3,5 yearperitoneal cavity recurrence rate were 5.6%,20.6%and 27.8%,53% in IPHPC group and CV group.There were significant differences in survival rate and peritoneal recurrence rate between the two groups.Conclusion:Intraperitoneal hyperthermic perfusion chemotherapy combined with venoclysis can prevent recurrence and metastasis effectively,and improve the survival rate and quality of life of postoperative gastric cancer patients. 毕业论文 【KEY WORDS】Stomach neoplasms#12539;Intraperitoneal hypethermic perfusion chemotherapy#12539;Chemotherapy of venoclysis 　胃癌施行手术治疗后，仍有50%以上的患者死于肿瘤的腹膜种植复发［1］，所以防治腹膜种植复发对提高胃癌疗效十分重要。为探讨腹腔热灌注化疗的疗效，我们于1999年开始对胃癌术后患者分别观察腹腔热灌注化疗联合静脉化疗和静脉化疗效果，现将结果报告如下。 毕业论文 1 资料与方法 1.1 一般资料 1999年1月至2002年12月，140